| Stage |
Phase |
Principal Investigator |
Study prefix |
Study number |
Title
(click hyperlink for more information) |
| I | Marwan Fakih, MD | I | 55305 | A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) in Combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) in Patients with Colorectal Cancer and other Solid Tumors(NCI#6789) |
| Advanced Malignancies | I | Renuka Iyer, MD | I | 23204 | An Open-Label, Dose Escalation study of Paricalcitol (Zemplar TM) {19-NOR-1 ALPHA, 25-(OH)2 D2] in Combination with Gemcitabine (Gemzar) [2',2' Diflurodeoxycytidine] in patients with advanced Malignancies |
| N/A | I | Todd Demmy, MD | I | 05903 | A Phase I Study of Light Dose for Photodynamic Therapy(PDT) Using 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a (HPPH) for treatment of Bronchogenic Carcinoma in situ or bronchogenic Microinvasive Carcinoma. A Dose Ranging Study |
| I | Alex Adjei, MD PhD | I | 157809 | (TAK-733-C20001) A Multicenter, Open-Label, Dose-Escaltion, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies |
Print This Page
